Venus Remedies Ltd. said it had received its first patent for a novel antibiotic combination of carbapenem and aminoglycoside.
Pioneering into antibacterial portfolio, Venus has added another international patent from Companies and Intellectual Property Registration office (CIPRO), South Africa, to its basket for the antibiotic combination rationally designed to result in a pharmaceutical low dose.
Novel antibiotic combination is suitable for the treatment of bacterial/multi-bacterial infections, and is particularly suitable for catering to the needs of all age groups ranging from the neonates, children, immuno compromised patients, and the one prone to serious fatal mixed multi-bacterial infectious diseases.
In case of neonates and children, where higher doses may precipitate serious toxicities and lower doses of existing therapies do not work, dose reduction to a therapeutically effective level with reduced side effects was the greatest accomplishment with the novel antibiotic combination.
Overall, the company is enjoying a total tally of more than 80 patents for its innovative research products across the globe.
With this patent grant from CIPRO, the company is hopeful of capturing a major share in the market which is upheaval with antibiotics for wide indications. With probable prolonged administration of most of the existing therapies, this proposed single unit injection will be a blessing for the medical fraternity as it is extremely effective even at very low concentrations. This will significantly overcome the drug resistance problem and will also reduce the side effects.
The global anti-infectives market generated revenues of $79.12 billion from second quarter of 2008 to second quarter of 2009. Over this period, the systemic antibacterial market accounted for around 47 percent of this market segment reaching $37.14 billion in revenues. Overall growth for the forecast period from 2009 to 2024 is estimated to be around seven percent (CAGR) rising to a figure of $99.13 billion, the company said.
The company said the product was under development in accordance with the stringent international guidelines defined for developing a new drug. Efficacy and safety studies established through a series of microbiological studies carried out as per CLSI guidelines. Venus expects the product to be in market by end of 2015 after regulatory approvals.
At the BSE, Venus Remedies closed Tuesday's trading at Rs.164.85, up 2.77 percent from the previous close.
For comments and feedback: editorial@rttnews.com